Enbrel pharmaceuticals arthritis releif
Enbrel also known by its generic name etanercept is a medication approved by the U S Food and Drug Administration FDA in April 2004 for the treatment of plaque psoriasis and in January 2002 for the treatment of psoriatic arthritis It is also approved for treating rheumatoid arthritis juvenile rheumatoid arthritis and ankylosing spondylitis arthritis affecting the spine FDA approved for treating psoriasis and psoriatic arthritis Patients give themselves injections under the skin twice weekly Taken continuously to maintain releif Minor allergic like reactions can occur where the injection is given Enbrel blocks tumor necrosis factor alpha TNF alpha a chemical messenger in the immune system that signals other cells to cause inflammation There is too much TNF alpha in the skin of people with psoriasis and the joints of people with certain types of arthritis which causes inflammation and can lead to tissue and joint damage TNF alpha can also lead to increased immune system activity through the activation of T cells T cells are a type of white blood cell in the body in psoriasis once T cells are mistakenly activated they can trigger inflammation and other immune responses and fuel the development of psoriasis lesions Enbrel helps lower the amount of TNF alpha to more normal levels thus interrupting the inflammatory cycle of psoriasis and psoriatic arthritis and leading to improvement in symptoms for many people who use the medication
Size: 3390px × 5085px
Photo credit: © Scenics & Science / Alamy / Afripics
License: Licensed
Model Released: No
Keywords: arthritis, enbrel, osteo, pharmaceuticals, releif
